NeuroOne Medical Technologies (NeuroOne Medical Technologies) Cash-to-Debt : 17.41 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NeuroOne Medical Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 17.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NeuroOne Medical Technologies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for NeuroOne Medical Technologies's Cash-to-Debt or its related term are showing as below:

NMTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 17.41 Max: No Debt
Current: 17.41

During the past 13 years, NeuroOne Medical Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 17.41.

NMTC's Cash-to-Debt is ranked better than
77.93% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: 1.91 vs NMTC: 17.41

NeuroOne Medical Technologies Cash-to-Debt Historical Data

The historical data trend for NeuroOne Medical Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NeuroOne Medical Technologies Cash-to-Debt Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

3.06

21.84

54.88

28.92

NeuroOne Medical Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															28.00	18.84	14.34	28.92	17.41

Competitive Comparison of NeuroOne Medical Technologies's Cash-to-Debt

For the Medical Devices subindustry, NeuroOne Medical Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Cash-to-Debt falls into.

NeuroOne Medical Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NeuroOne Medical Technologies's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.322	/	(0.129	+	0.055)
	=	28.92

NeuroOne Medical Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.681	/	(0.133	+	0.021)
	=	17.41

NeuroOne Medical Technologies (NAS:NMTC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NeuroOne Medical Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

7599 Anagram Dr., Eden Prairie, MN, USA, 55344

Website

https://www.n1mtc.com

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Executives

Mark Christianson	10 percent owner, officer: VP, Business Dev and Marketing	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg	officer: Chief Financial Officer	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director, officer: CEO and President	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris	officer: VP of Marketing	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank	10 percent owner	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p.	10 percent owner	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson	10 percent owner	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens	officer: Chief Technology Officer	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler	officer: Vice President of Sales	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia	director	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347